LoadingLoadingLoadingNet selling: insiders sold $399K and bought $0 on the open market in 90 days (SEC Form 4). Congress: net selling of $1K to $15K in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (3)
Citadel
$49.8M
added
Susquehanna
$31.0M
added
Balyasny
$26.9M
bought
Sells (1)
No tracked top-trader positions in ALNY as of Oct 24, 09:23 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Jul 30, 2026
Financial period
Q2
Earnings per share
$1.44 expected
Revenue
Company release
Company adjusted EPS: $1.84. Company and provider EPS differ; bases unknown.
FY 2026 guidance
$4.70B to $5.10B
No comparable estimate
Estimates as of Oct 24, 2026
EPS expected
$1.87 to $3.12
Revenue expected
21 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 30, 2026 | $1.21 / $1.44Alpha Vantage | -15.97% miss | $1.29B No estimate | Unavailable |
| Mar 31, 2026 | Apr 30, 2026 | $1.99 / $1.47Alpha Vantage | +35.37% beat | $1.17B No estimate | Unavailable |
| Dec 31, 2025 | Feb 12, 2026 | $1.25 / $1.50Alpha Vantage | -16.67% miss | $1.10B No estimate | Unavailable |
| Sep 30, 2025 | Oct 30, 2025 | $2.90 / $1.75Alpha Vantage | +65.71% beat | $1.25B No estimate | Unavailable |
| Jun 30, 2025 | Jul 31, 2025 | $0.32 / $0.15Alpha Vantage | +113.33% beat | $773.7M No estimate | Unavailable |
| Mar 31, 2025 | May 1, 2025 | -$0.01 / -$0.37Alpha Vantage | +97.30% beat | $594.2M No estimate | Unavailable |
| Dec 31, 2024 | Feb 13, 2025 | $0.06 / -$0.14Alpha Vantage | +142.86% beat | $593.2M No estimate | Unavailable |
| Sep 30, 2024 | Oct 31, 2024 | -$0.50 / -$0.39Alpha Vantage | -28.21% miss | $500.9M No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.25B | $1.10B | $1.17B | $1.29B |
| Cost of what it sold | $197.2M | $267.7M | $211.1M | $298.3M |
| Gross profit | $1.05B | $829.3M | $956.1M | $992.7M |
| What it spent | ||||
| Research and development | $358.8M | $372.2M | $364.9M | $413.1M |
| Sales and admin | $322.1M | $325.4M | $322.6M | $347.9M |
| Total operating expenses | $683.8M | $697.6M | $687.4M | $761.2M |
| What was left | ||||
| Operating profit | $368.0M | $131.7M | $268.6M | $231.4M |
| Interest on debt | $44.4M | $129.3M | $69.3M | $82.1M |
| Profit before tax | $239.0M | $161.1M | $221.7M | $177.8M |
| Tax | -$12.1M | -$25.3M | -$15.7M | $13.3M |
| Net profit | $251.1M | $186.4M | $206.0M | $164.5M |
| EBITDA | $297.2M | $304.0M | $304.5M | $245.1M |
This stock is under pressure.
Trend
Under pressure
15 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is mixed
Alnylam Pharmaceuticals (ALNY) Cuts 2026 Guidance After AMVUTTRA Sales Beat, Is It Fully Valued
NeutralOct 22Is Lower AMVUTTRA Guidance Altering The Investment Case For Alnylam Stock?
NeutralOct 21Wells Fargo cuts Alnylam target to USD 253 for Alnylam Pharmaceuticals stock
Leans bearishOct 20BofA cuts target to USD 336.00 for Alnylam Pharmaceuticals stock
Leans bearishOct 17What Has Changed For Alnylam Pharmaceuticals Since Its 52% Fall
NeutralOct 17Alnylam founder's new biotech lands $200M in upsized IPO
Leans bullishOct 16Alnylam Pharmaceuticals Is Maintained at Buy by Citigroup
BullishOct 15Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results
NeutralOct 15
